Background {#Sec1}
==========

HIV-1 subtype is associated with disease pathogenesis and progression of AIDS \[[@CR1]\]. For example, patients infected with HIV-1 subtype D experience a more rapid progression to AIDS compared with subtypes A and B \[[@CR2], [@CR3]\]. Untreated patients infected with HIV-1 CRF01_AE subtype have a shorter median survival than patients of subtype B \[[@CR4]--[@CR6]\]. This finding may be explained by the predominant association of HIV-1 CRF01_AE subtype with CXCR4 rather than CCR5 tropism, or coreceptor switch of R5/X4 with prolonged infection time, ultimately leading to a more rapid disease progression \[[@CR7], [@CR8]\].

To date, the HIV-1 DNA reservoir and recovery of replication-competent HIV in antiretroviral therapy (ART) treated patients with undetectable HIV-1 RNA remains the major obstacle in identifying a cure for HIV \[[@CR9]\]. The HIV reservoir is influenced by multiple factors, including the clinical stage of HIV infection, CD4^+^ T cell count, CD4/CD8 ratio, degree of immune activation/inflammation, treatment duration, and HIV-associated neurocognitive disorders \[[@CR10]--[@CR15]\]. As a biomarker, HIV-1 DNA level is usually used to evaluate the persistence and dynamics of the HIV reservoir \[[@CR14]\]. Moreover, the HIV-1 DNA reservoir in PBMCs prior to initiation of ART can predict viral rebound after treatment interruption, and is independently correlated with disease progression \[[@CR16], [@CR17]\].

Although HIV-1 subtype and HIV-1 DNA levels have each been independently associated with disease progression, the correlation between HIV-1 viral subtype and HIV-1 DNA kinetic changes remains unclear. We performed an analysis of data collected as part of two prospective, multi-site cohort studies to explore the influence of CRF01_AE subtype, the predominant subtype in China, on HIV-1 total DNA level across different time points during the 96 weeks after ART, and to identify baseline predictors of achieving low HIV-1 DNA levels (≤ 2 log~10~ copies/10^6^ PBMCs) after 96 weeks of ART.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

We performed a secondary analysis of stored samples collected from HIV-1 infected patients enrolled in two large multi-centre, open-label clinical trials prospectively evaluating the efficacy and toxicities associated with approved ART regimens available through the China National Free AIDS Treatment Program respectively from 2008 to 2010 (cohort 1, NCT00872417) and 2012--2014 (cohort 4, NCT01844297). The studies were carried out by the China AIDS Clinical Trial Network in 11 different municipalities/provinces in China, including Beijing, Fujian, Guangdong, Guangxi, Henan, Hunan, Liaoning, Shanghai, Shanxi, Sichuan, and Yunnan provinces. The inclusion and exclusion criteria and study-related procedures of these clinical trials have been previously described in detail \[[@CR18]--[@CR20]\].

The additional criteria for patient inclusion in the present study were as follows: completed at least 96 weeks of follow up with HIV-1 RNA levels maintained ≤50 copies/mL after 48 weeks of ART, 12 patients (10 in CRF01_AE group, 2 in non-CRP01_AE group) experienced viral blips (HIV-1 RNA ≤ 200 copies/mL) were allowed in this study.

As part of the parent studies, sociodemographic and clinical data including sex, age, ethnicity, route of transmission, marital status, and smoking history were collected at the time of study enrolment. Baseline CD4^+^ and CD8^+^ T cell counts, HIV-1 RNA load, and HIV-1 DNA level were also measured for all participants. Follow-up evaluations were performed at weeks 0/12/24/48/96. Peripheral blood samples (plasma, whole blood) were collected at each time point and stored at − 80 °C.

HIV-1 nucleic acid quantification {#Sec4}
---------------------------------

HIV-1 total DNA was extracted from the peripheral blood by using MagNA Pure LC DNA Isolation Kit and MagNA Pure LC instrument (Roche Molecular Biochemicals, Mannheim, Germany), amplified and quantified using LTR gene primers with a real-time fluorescence-based HIV detection kit (SUPBIO, Guangzhou, China) \[[@CR21]\],the reaction system contains: reaction mixture (44.2 μL), enzyme (0.8 μL), HIV-1 DNA (5 μL). Finally, HIV-1 DNA per 10^6^ PBMCs was calculated by dividing the proportion of lymphocytes and monocytes in the routine complete blood count. The quantification range for HIV-1 DNA using this assay was 20 to 5,000,000 copies/10^6^ WBCs.

HIV-1 RNA was extracted from plasma using the QIAamp RNA mini kit (QIAGEN, Hilden, Germany) and then amplified using the COBAS Ampliprep/TaqMan48 real-time RT-PCR Test (Roche Diagnostics, Indianapolis, Indiana, USA). The detection range of HIV-1 RNA was 40 to 10, 000, 000 copies/mL.

HIV-1 subtype analysis {#Sec5}
----------------------

The HIV Pol gene was amplified with PrimeScript One Step RT-PCR Kit Ver.2 (TaKaRa, Dalian, China) and then sequenced. PCR primers used for sequencing have been reported previously \[[@CR7]\]. Subtypes of HIV-1 were then determined through the Recombinant Identification Program (<http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html>) and confirmed by neighbour joining phylogenetic analysis via sequence alignment of the Pol gene with reference sequences from the Los Alamos National Laboratory (<http://www.hiv.lanl.gov/content/index>). In order to further confirm the HIV-1 subtype, sequencing of the V3 loop was also carried out in patients (*n* = 76) preliminarily determined by Pol gene sequencing.

Statistical analysis {#Sec6}
--------------------

The patients' baseline clinical and demographic characteristics were compared between HIV-1 subtype groups using the Student's t-test for parametric continuous variables, and Wilcoxon Rank Sum test for non-parametric continuous variables.

Patients were classified into 3 categories according to their HIV-1 DNA levels at 96 weeks (high: ≥ 3 log~10~, moderate: 2--3 log~10~, and low: ≤ 2 log~10~ copies/10^6^ PBMCs). Differences in the proportion of patients in each group by subtype CRF01_AE and non-CRF01_AE were analysed by Chi squared analysis. Univariate and multivariable logistic regression using the forward entry method to assess the correlation between HIV-1 total DNA level at 96 weeks (≤ 2 log~10~ copies/10^6^ PBMCs). Variables for which *P* \< 0.2 in the univariate analyses were included in the subsequent multivariable regression analysis.

All analyses were performed using SPSS version 19.0 (IBM Corporation, Armonk, New York, USA) and GraphPad Prism 6.0 (GraphPad Software, Inc. La Jolla, CA, USA). *P* values \< 0.05 were considered statistically significant.

Results {#Sec7}
=======

Population characteristic {#Sec8}
-------------------------

Of the total 999 patients enrolled in the two parent studies (499 patients in NCT00872417 and 500 patients in NCT01844297), 373 patients met the inclusion criteria and were classified into CRF01_AE subtype (*n* = 188, 50.4%) and non-CRF01_AE subtype (*n* = 185, 49.6%) groups. The non-CRF01_AE group included subtypes B, C, CRF07_BC, CRF08_BC and URF). The characteristics of the study population are summarized in Table [1](#Tab1){ref-type="table"}. There were no significant differences between the two subtype groups regarding to sex, age, ethnicity, and ART therapy. However, prior to ART initiation, the CRF01_AE group showed significantly higher plasma HIV-1 RNA levels (4.83 vs. 4.49 log~10~ copies/mL, *P* \< 0.001), higher total DNA levels (3.19 vs. 2.95 log~10~ copies/10^6^ PBMCs, *P* = 0.001), lower CD4^+^ T cell count (193 vs. 246 cells/μL, *P* = 0.001) and CD4/CD8 ratio (0.23 vs. 0.27, *P* = 0.006) compared with non-CRF01_AE group. Table 1Sociodemographic and clinical characteristics of the study population, stratified by HIV-1 subtypeTotal *N = 373*CRF01_AE *n = 188*Non-CRF01_AE *n = 185P-*valueSex n(%)0.429 Male263 (70.5)129 (68.6)134 (72.4) Female110 (29.5)59 (31.4)51 (27.6) Age years35 (27--43)35 (28--43)36 (27--43)0.893Ethnic category n(%)0.655 Han321 (86.1)157 (83.5)164 (88.6) Minority52 (13.9)31 (16.5)21 (11.4)Route of Transmission n(%)0.002MSM120 (32.2)65 (34.6)55 (29.7)Heterosexual195 (52.3)106 (56.4)89 (48.1)Others58 (15.5)17 (9.0)41 (22.2)Time between diagnosis and ART initiation (years)0.26 (0.99--1.18)0.32 (0.11--1.57)0.22 (0.09--0.97)0.245Baseline HIV-1 DNA log~10~ copies/mL3.0 (2.6--3.4)3.19 (2.7--3.5)2.95 (2.6--3.2)0.000Baseline plasma viral load log~10~ copies/mL4.6 (4.2--5.1)4.83 (4.4--5.2)4.49 (3.8--4.9)0.000Baseline CD4^+^ T cell count cells/μL214 (129--299)193 (103--286)246 (157--206)0.001Baseline CD8^+^ T-cell count cells/μL788 (530--1080)733 (526--1058)835 (545--1113)0.391Baseline CD4/CD8 ratio0.24 (0.15--0.37)0.23 (0.11--0.35)0.27 (0.18--0.41)0.00696-week HIV-1 DNA log~10~ copies/mL2.53 (2.09--2.91)2.63 (2.21--2.97)2.39 (2.00--2.80)0.002Continuous variables are expressed as median (interquartile range). Abbreviations: ART, Antiretroviral therapy; PBMCs, Peripheral blood mononuclear cells

HIV-1 DNA dynamics {#Sec9}
------------------

Although HIV-1 RNA levels were equally supressed in both groups, and no significant difference was observed in CD4^+^ T cell recovery over 96 weeks (Figs. [1](#Fig1){ref-type="fig"}a & b), the HIV-1 DNA levels remained consistently higher in the CRF01_AE group compared with the non-CRF01_AE group \[2.62(2.21--2.97) vs. 2.38(2.00--2.80) log~10~ copies/10^6^ PBMCs at week 96 (*P* = 0.002)\] (Figs. [1](#Fig1){ref-type="fig"}c & d). The largest decrease occurred during the first 24 weeks of treatment in both groups. At week 24, the median change in HIV-1 DNA from baseline was similar in both groups \[− 0.53 (− 0.86 to − 0.28) log~10~ copies/10^6^ PBMCs in the CRF01_AE group vs. − 0.66 (− 1.01 to − 0.29) log~10~ copies/10^6^ PBMCs in the non-CRF01_AE group, *P* = 0.181\]. HIV-1 DNA levels plateaued thereafter until week 96 (Fig. [1](#Fig1){ref-type="fig"}c). Fig. 1Dynamic changes of clinical parameters during 96 weeks of ART between CRF01_AE and non-CRF01_AE group. **a**. HIV-1 viral load of both groups was controlled efficiently. **b**. Increased CD4^+^ T cell count after ART in both of the two groups. **c**. The HIV-1 DNA level of CRF01_AE is higher than that of non-CRF01_AE group through all the treatment period. **d**. The decay of HIV-1 DNA level at baseline and week 96. **e**. The distribution of individuals classified by HIV-1 DNA level at week 96 (High: HIV-1 DNA level ≥ 3 log10 copies/10^6^ PBMCs; Moderate: HIV-1 DNA level between 2 and 3 log10 copies/10^6^ PBMCs; Low: HIV-1 DNA level ≤ 2 log10 copies/10^6^ PBMCs)

As pre-ART CD4+ T-cell count and pre-ART HIV-1 DNA showed a strong, negative correlation \[[@CR22]--[@CR24]\], we screened 325 patients (213 from cohort 1, 112 from cohort 4) with a baseline CD4^+^ T ≤ 350 cells/μL to further analysis the relationship between HIV-1 DNA dynamics and the specific antiretroviral regimens. Results showed that the largest decrease in both of cohort 1 and 4 occurred during the first 24 weeks of treatment, the median change from baseline to week 24 was similar in both cohorts \[− 0.67 (− 1.03 to − 0.29) log~10~ copies/10^6^ PBMCs in cohort 1 vs. − 0.47 (− 0.73 to − 0.26) log~10~ copies/10^6^ PBMCs in cohort 4, *P* = 0.574\] (Additional file [1](#MOESM1){ref-type="media"}: Fig. S1a), HIV-1 DNA decline between the two subtypes has also no significant difference in cohort 1 \[CRF01_AE group vs. non-CRF01_AE group: − 0.68 (− 1.03 to − 0.29) vs. -0.70 (− 1.01 to − 0.36), *P* = 0.181\] (Additional file [1](#MOESM1){ref-type="media"}: Fig. S1b) and cohort 4 \[− 0.48 (− 0.73 to − 0.25) vs. -0.46 (− 0.78 to − 0.12). *P* = 0.570\] (Additional file [1](#MOESM1){ref-type="media"}: Fig. S1c).

The relationship between HIV-1 subtype and HIV-1 DNA level {#Sec10}
----------------------------------------------------------

To analyse the relationship between HIV-1 subtype and HIV-1 DNA level of the overall study population, the DNA levels at week 96 were categorized into high, moderate and low levels with mean total HIV-1 DNA levels of 3.16 (3.12--3.30), 2.53 (2.28--2.73) and 1.73 (1.46--1.91) log~10~ copies/10^6^ PBMCs, respectively (Fig. [1](#Fig1){ref-type="fig"}e) and their corresponding distribution were 18.5% (69/373), 60.1% (224/373) and 21.4% (80/373) (Fig. [1](#Fig1){ref-type="fig"}e & Table [2](#Tab2){ref-type="table"}). When further stratified by subtype into CRF01_AE and non-CRF01_AE, there was no difference in the proportion of patients in the 3 categories at week 96 (Table [2](#Tab2){ref-type="table"}). Table 2Category of HIV-1 DNA level at week 96 by subtypeHIV-1 DNA level at 96 weeks n (%)CRF01_AE *n = 188*Non-CRF01_AE *n = 185P-value*High42 (22.3%)27 (14.6%)0.054Moderate112 (59.6%)112 (60.5%)0.849Low34 (18.1%)46 (24.9%)0.111High: HIV-1 DNA ≥ 3 log10 copies/10^6^ PBMCs; Moderate: HIV-1 DNA between 2 and 3 log10 copies/10^6^ PBMCs; Low: HIV-1 DNA ≤ 2 log10 copies/10^6^ PBMCs. Differences in the proportion of patients in each group were analysed by Chi squared analysis

Association between sociodemographic and clinical risk factors and low HIV-1 DNA level at week 96 {#Sec11}
-------------------------------------------------------------------------------------------------

In our univariate logistic regression analysis, sex, HIV-1 subtype, baseline CD4^+^ T cell count, CD4/CD8 ratio, and baseline HIV-1 RNA levels were associated with low HIV-1 DNA levels at 96 weeks (Table [3](#Tab3){ref-type="table"}). In the multivariable model, lower baseline HIV-1 DNA level \[OR = 0.489 (0.005--0.714), *P* = 0.000\] and baseline CD4^+^ T cell count \> 200 cells/μL \[OR = 3.341 (1.712--6.520), *P* = 0.000\] were predictors for achieving a HIV-1 DNA level of ≤2 log~10~ copies/10^6^ PBMCs (Table [3](#Tab3){ref-type="table"}), but not HIV-1 subtype \[OR = 1.279, (0.721--2.266), *P* = 0.400\] (Table [3](#Tab3){ref-type="table"}). Table 3Association between clinical risk factors and achieving HIV-1 DNA \< 2 log10 copies/10^6^ PBMCsVariablesUnivariateOR (95% CI)MultivariateOR (95% CI)*P-valueP-value*Sex Male11 Female1.758 (1.045--2.957)0.0341.447 (0.725--2.885)0.294Age years 18--3511 36--501.439 (0.594--3.487)0.4211.328 (0.499--3.534)0.570  \> 500.850 (0.335--2.159)0.7330.801 (0.291--2.206)0.668Transmission route Homosexual11 Heterosexual2.789 (1.009--7.715)0.0483.024 (0.983--9.302)0.54 Others3.558 (1.345--9.407)0.0112.961 (1.017--8.622)0.05HIV-1 subtype CRF01_AE11 Non-CRF01_AE1.554 (0.941--2.569)0.0851.279 (0.721--2.266)0.400Baseline CD4 T cell count cells/μL  \< 20011  \> 2004.903 (2.634--9.124)0.0003.341 (1.712--6.520)0.000Baseline CD4/CD8 ratio  \< 0.511  \> 0.51.948 (0.953--3.979)0.0671.475 (0.663--3.282)0.341Baseline HIV-1 DNA log 10 copies/10^6^ PBMCs0.380 (0.261--0.555)0.0000.489 (0.335--0.714)0.000Baseline HIV-1 RNA log 10 copies/10^6^ PBMCs0.758 (0.590--0.974)0.0000.985 (0.722--1.344)0.923Abbreviations: OR, Odds ratio; CI, Confidence interval; ART, Antiretroviral therapy; PBMCs, Peripheral blood mononuclear cells

Discussion {#Sec12}
==========

This study explored the effect of HIV-1 CRF01_AE subtype on HIV-1 DNA levels over a 96-week period. Our results demonstrate that HIV-1 CRF01_AE infected patients harbour a higher level of HIV-1 DNA throughout the 96-week period compared with patients with other subtypes. However, CRF01_AE subtype does not appear to affect HIV-1 DNA reservoir decline. After 96 weeks, approximately 20% of patients in both groups achieved HIV-1 DNA level ≤ 2 log~10~ copies/10^6^ PBMCs, and HIV-1 subtype was not found to be an independent risk factor for predicting low HIV-1 DNA levels at week 96. Previous studies mainly focused on the impact of viral subtype on the level of HIV-1 RNA and CD4^+^ T cell count, but rarely on HIV-1 DNA \[[@CR7], [@CR8]\]. To our knowledge, this is the first national multicentre prospective cohort study in the world to assess the relationship of subtype and HIV-1 DNA reservoir after ART \[[@CR25]\].

The median HIV-1 DNA level of our patients at baseline was ∼3 log~10~ copies/10^6^ PBMCs. We observed a period of more rapid decline in HIV-1 DNA during the first 24 weeks of ART, followed by a plateau through week 96, a finding which is consistent with previous studies \[[@CR22], [@CR26]\]. This pattern of change is likely due to more rapid degradation of linear HIV-1 DNA present in the early period of ART initiation compared with slower and more difficult elimination of integrated HIV-1 DNA that forms the HIV-1 reservoir later in the course of treatment \[[@CR27], [@CR28]\]. HIV-1 DNA level is higher among patients with the CRF01_AE subtype before and after ART (Fig. [1](#Fig1){ref-type="fig"}c) and a small gap remains at week 96, therefore, higher pre-treatment HIV-1 DNA level in HIV-1 CRF01_AE patients should be aroused much attention and strengthen surveillance during ART.

Lower HIV-1 DNA levels have been shown to be predictive of a longer period to viral rebound after ART interruption \[[@CR29], [@CR30]\]. Despite the reduction in HIV-1 DNA levels observed in our study, approximately 20% patients in both groups were able to achieve a low level (median 1.73 log~10~ copies/10^6^ PBMCs), this reservoir level is similar to post-treatment controllers in the VISCONTI cohort (French), 14 post-treatment HIV-1 controllers with a long-term virological remission after early treatment interruption among 70 patients, and this 14 patients harbour a lower DNA reservoir (median 1.71 log~10~ copies/10^6^ PBMCs) \[[@CR29]\]. Because lower HIV-1 DNA level associated with a longer time to viral rebound, therefore, we predicted that 21.4% patients (low DNA category patients in two groups) in our study maybe preferred candidates for further study such as structured treatment interruption.

Total HIV-1 DNA level is also a major predictor of progression to AIDS. A study followed 383 patients in the Seroconverter Cohort (SEROCO, a French prospective cohort) study for more than 8 years, and found the relative risk of progression to AIDS for each 1-log~10~ increase in HIV-1 DNA level was 3.2 \[[@CR31]\], while higher CD4^+^ T cell level \[[@CR32]\], higher CD4/CD8 ratio, and a lower level of HIV RNA before treatment predicted a more robust therapeutic effect \[[@CR14]\]. In our study, higher baseline CD4^+^ T cell count and lower baseline HIV-1 DNA were associated with achieving a low HIV-1 DNA level after ART, which is consistent with previous studies \[[@CR22], [@CR33]\]. Furthermore, the time of HIV-1 infection to treatment initiation has been reported as a factor influencing decay total HIV DNA levels during ART \[[@CR34], [@CR35]\]. In our study, although the HIV-1 DNA level in both groups declined significantly after ART (Figs. [1](#Fig1){ref-type="fig"}c&d), the CRF01_AE subtype exhibited a higher level at baseline, which may explain the higher DNA levels observed at week 96 (Fig. [1](#Fig1){ref-type="fig"}d). In contrast, Lu performed a study of 48 patients in Guangxi province (China), followed for 18 months and found the decline in total HIV-1 DNA was significantly faster among patients with the CRF01_AE subtype than in those with subtypes B and CRF07_BC \[[@CR25]\]. The ratio of CXCR4-usage for clones from CRF01_AE in our study was higher than that of non-CRF01_AE subtypes (Additional file [1](#MOESM1){ref-type="media"}: Table S1), which is similar to Lu's study. As to the reason why HIV-1 DNA level of 96 weeks of ART in CRF01_AE subtype is in contrast with those of Lu et al. \[[@CR25]\], other parameters such as the difference of baseline characteristic or HLA typing might also contribute to the discrepancy.

CRF01_AE has been shown to be associated with a lower CD4^+^ T cell count and higher rates of CXCR4 co-receptor \[[@CR7], [@CR8], [@CR36]\]. In our study, baseline CD4^+^ T cell count was lower in the CRF01_AE group than the non-CRF01_AE group. Similar to a previous study \[[@CR37]\], the CD4^+^ T cell count in both groups increased sharply after ART, reaching a similar level at week 12 (Fig. [1](#Fig1){ref-type="fig"}b). At the same time, baseline CD4^+^ T cell count and HIV-1 DNA level but not the viral subtypes, were predictors for achieving HIV-1 DNA ≤ 2 log~10~ copies/10^6^ PBMCs, which is in agreement with previous studies \[[@CR33]\]. The influence of subtype specific differences on disease progression may play a less prominent role in HIV-DNA levels after ART initiation \[[@CR38]\].

Limitations {#Sec13}
-----------

This study has a few limitations that warrant mention. First, patients were classified into CRF01_AE and non-CRF01_AE groups, without evaluating the impact of other subtypes. We haven't conduct V3 sequence in whole patients and without follow-up sequences. In addition, other factors, which likely contribute to disease progression, such as immune activation, human leukocyte antigen genotypes, as well as HIV-1 specific cytotoxic T lymphocyte response were not analysed in this study.

Conclusions {#Sec14}
===========

Patients infected with HIV-1 CRF01_AE subtype had higher HIV-1 DNA levels at baseline, but a similar pattern of decline in HIV-1 DNA levels during 96 weeks of ART. Baseline CD4^+^ T cell count and HIV-1 DNA level were associated with achieving HIV-1 DNA level ≤ 2 log~10~ copies/10^6^ PBMCs at week 96, but not HIV-1 subtype. Further research is warranted to explore the relationship between HIV-1 DNA levels in other HIV-1 subtypes and reservoir persistence.
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**Additional file 1: Figure S1.** HIV-1 DNA dynamics stratified by ART therapy and subtype. **Table S1.** Predicted co-receptor usage based on V3 loop sequence (*n* = 76)
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